NIFTY23,406▼0.33%

SENSEX74,346▼0.41%

BANKNIFTY54,186▲0.88%

NIFTY IT29,384▼5.57%

PHARMA24,087▲0.33%

AUTO26,093▲0.05%

FMCG48,124▼1.01%

METAL13,535▼0.17%

REALTY762.60▼1.39%

ENERGY40,197▲0.02%

NIFTY23,406▼0.33%

SENSEX74,346▼0.41%

BANKNIFTY54,186▲0.88%

NIFTY IT29,384▼5.57%

PHARMA24,087▲0.33%

AUTO26,093▲0.05%

FMCG48,124▼1.01%

METAL13,535▼0.17%

REALTY762.60▼1.39%

ENERGY40,197▲0.02%

IPOMar 5, 2026

Win-Medicare Seeks $150-200 Million Stake Sale, Engages EY as Advisor

Minority Stake Sale by Win-Medicare Pvt Ltd

Win-Medicare Pvt Ltd, a subsidiary of Umesh Modi Group, is planning to sell a minority stake in the company. The sale is expected to be valued between $150 million and $200 million.

According to sources, Win-Medicare Pvt Ltd, which owns household brands such as Betadine and Movicol, has appointed EY as its advisor to lead the search for potential buyers. The stake sale is part of the company's strategy to raise capital and potentially pursue further growth opportunities.

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

Investor Takeaway

Investors should be aware of the potential minority stake sale in Win-Medicare Pvt Ltd.

More in IPO

IPO·43m ago

SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

IPO·9h ago

SMR Jewels IPO Successfully Lists with Institutional Support

IPO·10h ago

Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO

IPO·10h ago

Merritronix IPO Sees Robust Subscription, Oversubscribed by 293 Times on Final Day

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO Calendar GMP Tracker Subscription Status Allotment Status

IPOs

All IPOs Live IPOs Upcoming IPOs Closed IPOs Listed IPOs

Resources

News eBooks

Company

Home Privacy Policy Terms of Service

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.